(S)-N-[3-(3-氟-4-碘-苯基)-2-氧代-唑烷-5-甲基]-乙酰氨 | 149524-45-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (S)-N-[3-(3-氟-4-碘-苯基)-2-氧代-唑烷-5-甲基]-乙酰氨
• 中文别名: (S)-N-[3-(3-氟-4-碘-苯基)-2-氧代-噁唑啉-5-甲基]-乙酰胺
• 英文名称: (5S)-N-[3-(3-fluoro-4-iodophenyl)-2-oxo-oxazolidin-5-ylmethyl]acetamide
• 英文别名: (S)-N-((3-(3-fluoro-4-iodophenyl)-2-oxooxazolidin-5-yl)methyl)acetamide；(S)-N-[3-(3-Fluoro-4-iodo-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-acetamide；N-[[(5S)-3-(3-fluoro-4-iodophenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
• CAS: 149524-45-8
• 化学式: C₁₂H₁₂FIN₂O₃
• 分子量: 378.142
• InChiKey: YLWDRZMLYRIMNV-VIFPVBQESA-N

物化性质

• 沸点：
  520.6±40.0 °C(Predicted)
• 密度：
  1.736±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  (S)-N-[3-(3-氟-4-碘-苯基)-2-氧代-唑烷-5-甲基]-乙酰氨 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 甲酸 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.5h， 生成 N-[((5S)-3-{4-[(E)-3-(dimethylamino)-2-propenoyl]-3-fluorophenyl}-2-oxo-1,3-oxazolidin-5-yl)methyl]acetamide
  参考文献：
  名称：

  Carbon–carbon-linked (pyrazolylphenyl)oxazolidinones with antibacterial activity against multiple drug resistant gram-positive and fastidious gram-negative bacteria

  摘要：

  In an effort to expand the spectrum of activity of the oxazolidinone class of antibacterial agents to include Gram-negative bacteria, a series of new carbon-carbon linked pyrazolylphenyl analogues has been prepared. The alpha -N-substituted methyl pyrazole (10 alpha) in the C3-linked series exhibited very good Gram-positive activity with MICs less than or equal to 0.5-1 mug/mL and moderate Gramnegative activity with MICs = 2-8 mug/mL against Haemophilus influence and Moraxella catarrhalis. This analogue was also found to have potent in vivo activity with an ED50 = 1.9 mg/kg. beta -Substitution at the C3-linked pyrazole generally results in a loss of activity. The C4-linked pyrazoles are slightly more potent than their counterparts in the C3-linked series. Most of the analogues in the C4-linked series exhibited similar levels of activity in vitro, but lower levels of activity in vivo than 10 alpha. In addition, incorporation of a thioamide moiety in selected C4-linked pyrazole analogues results in an enhancement of in vitro activity leading to compounds several times more potent than eperezolid. linezolid and vancomycin. The thioamide of the N-cyanomethyl pyrazole analogue (34) exhibited an exceptional in vitro activity with MICs of less than or equal to 0.06-0.25 kg/mL against Gram-positive pathogens and with MICs of 1 mug/mL against fastidious Gram-negative pathogens. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00233-4
• 作为产物：
  描述：

  (S)-5-(氨基甲基)-3-(3-氟苯基)噁唑啉-2-酮 在 N-碘代丁二酰亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (S)-N-[3-(3-氟-4-碘-苯基)-2-氧代-唑烷-5-甲基]-乙酰氨
  参考文献：
  名称：

  掺入手性偕二取代氮杂环可产生具有降低线粒体毒性的恶唑烷酮抗生素。

  摘要：

  偕二取代的 N-杂环化合物在药物中很少被发现，尽管它们具有改善小分子药物的类药特性的潜力。利奈唑胺是一种含有吗啉杂环的恶唑烷酮抗生素，具有与人类线粒体蛋白质合成抑制相关的显着副作用。我们合成了一种偕二取代的利奈唑胺类似物，与利奈唑胺相比，它保持了可比的（尽管略有减弱）抗菌活性、可比的体外理化性质，并减少了不需要的线粒体蛋白质合成（MPS）抑制。这项研究有助于获得有关恶唑烷酮 MPS 抑制的结构-活性-关系数据，并可能激发对宝石二取代的 N-杂环在药物化学中的应用的研究。

  DOI：

  10.1016/j.bmcl.2019.07.024
• 作为试剂：
  描述：

  4-({tert-butoxycarbonyl-[1-(4-methoxybenzyl)-1H-[1,2,3 ]triazol-4-ylmethyl]amino}methyl)phenylboronic acid 、 (S)-N-[3-(3-氟-4-碘-苯基)-2-氧代-唑烷-5-甲基]-乙酰氨 、 4-({tert-butoxycarbonyl-[3-(4-methoxybenzyl)-3H-[1,2,3 ]triazol-4-ylmethyl]amino}methyl)phenylboronic acid 在 (S)-N-[3-(3-氟-4-碘-苯基)-2-氧代-唑烷-5-甲基]-乙酰氨 作用下， 以88的产率得到(5S)-{4'-[5-(acetylaminomethyl)-2-oxo-oxazolidin-3-yl]-2'-fluorobiphenyl-4-ylmethyl}-[1-(4-methoxybenzyl)-1H-[1,2,3 ]triazol-5-ylmethyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  WO2006133397A2

  摘要：

  公开号：

文献信息

• [EN] OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIALS<br/>[FR] DERIVES D'OXAZOLIDINONE UTILISES COMME AGENTS ANTIMICROBIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2006038100A1

  公开（公告）日：2006-04-13

  The present invention relates to certain substituted phenyl oxazolidinones and to processes for the synthesis of the same. This invention also relates to pharmaceutical compositions containing the compounds of the present invention as antimicrobials. The compounds are useful antimicrobial agents, effective against a number of human and veterinary pathogens, including gram-positive aerobic bacteria, for example, multiple-resistant staphylococci, streptococci and enterococci as well as anaerobic organisms, for example, Bacterioides spp. and Clostridia spp. species, and acid fast organisms, for example, Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium spp.

  本发明涉及某些取代苯基噁唑烷酮以及其合成方法。本发明还涉及含有本发明化合物作为抗微生物药物的药物组合物。这些化合物是有用的抗微生物剂，对多种人类和兽医病原体有效，包括革兰氏阳性厌氧细菌，例如多重耐药葡萄球菌、链球菌和肠球菌，以及厌氧生物，例如Bacterioides属和Clostridia属物种，以及耐酸生物，例如结核分枝杆菌、埃维分枝杆菌和分枝杆菌属。
• Novel oxazolidinone derivatives and a process for the preparation thereof
  申请人：——

  公开号：US20030166620A1

  公开（公告）日：2003-09-04

  The present invention relates to novel oxazolidinone derivatives, their pharmaceutically acceptable salts and a process for the preparation thereof. More particularly, the present invention relates to oxazolidinone derivatives having pyridine or pyrimidine moeity substituted by heterocycle and heteroaromaticcycle at 4-position of phenyl ring. The compounds of the present invention have wide antibacterial spectrum, superior antibacterial activity and low toxicity, such that the compound of this invention can be used as an antibacterial agent.

  本发明涉及新颖的噁唑烷酮衍生物，其药用盐以及其制备方法。更具体地，本发明涉及在苯环的4位被杂环和杂芳环取代的噁唑烷酮衍生物。本发明的化合物具有广泛的抗菌谱、优越的抗菌活性和低毒性，因此本发明的化合物可用作抗菌剂。
• [EN] OXAZOLIDINONE AND / OR ISOXAZOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS<br/>[FR] DERIVES D'OXAZOLIDINONE ET/OU D'ISOXAZOLINE UTILISES COMME AGENTS ANTIBACTERIENS
  申请人：ASTRAZENECA AB

  公开号：WO2004048392A1

  公开（公告）日：2004-06-10

  A compound of the formula (I), or a pharmaceutically-acceptable salt, or in-vivo hydrolysable ester thereof: formula (I) wherein in (I) C is for example formula (D), formula (E), formula (H) wherein A and B are independently selected from (i) formula (J) and (ii) formula (K) m is 1 or 2; R2b and R6b, R2a and R6a, R3a and R5a, are for example selected from H, F, OMe and Me; R2b' and R6b', R2a' and R6a', R3a', R5a' are for example selected from H, OMe and Me; R1a is for example optionally substituted (1-10C)alkyl; R1b is for example selected from -NR5C(=W)R4, formula (a) , or formula (b) wherein HET-1 is for example isoxazolyl and HET-2 is for example triazolyl or tetrazolyl. Methods for making compounds of the formula (I), compositions containing them and their use as antibacterial agents are also described.

  公式（I）的化合物，或其药用可接受盐，或体内可水解酯：公式（I）其中在（I）中，C例如为公式（D），公式（E），公式（H）其中A和B分别选自（i）公式（J）和（ii）公式（K）m为1或2；R2b和R6b，R2a和R6a，R3a和R5a，例如选自H，F，OMe和Me；R2b'和R6b'，R2a'和R6a'，R3a'，R5a'例如选自H，OMe和Me；R1a例如为可选择地取代的（1-10C）烷基；R1b例如选自-NR5C(=W)R4，公式（a），或公式（b）其中HET-1例如为异恶唑基，HET-2例如为三唑基或四唑基。还描述了制备公式（I）的化合物的方法，含有它们的组合物以及它们作为抗菌剂的用途。
• COFERONS AND METHODS OF MAKING AND USING THEM
  申请人：Barany Francis

  公开号：US20120295874A1

  公开（公告）日：2012-11-22

  The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.

  本发明涉及一种用于制备治疗性化合物的单体。该单体包括一个或多个可与目标分子结合的药效团，其解离常数小于300微摩尔，以及与药效团连接的连接元素。所述连接元素的分子量小于500道尔顿，通过直接连接或通过连接器间接与药效团相连。
• [EN] BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSES HÉTÉROCYCLIQUES DE BIARYLE ET PROCÉDÉS DE FABRICATION ET D'UTILISATION DESDITS COMPOSÉS
  申请人：RIB X PHARMACEUTICALS INC

  公开号：WO2006022794A1

  公开（公告）日：2006-03-02

  The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of tricyclic compounds that are useful as such agents.

  本发明总体上涉及抗感染、抗增殖、抗炎和促动力剂领域。更具体地说，本发明涉及一类用作上述药物的具有三环结构的化合物。